Colorectal cancer (CRC) is the third most common cancer among men and women and the second leading cause of cancer death in the Western world. 1 Nearly 25% of all patients have metastatic disease at initial diagnosis, with a five-year survival rate of less than 10%. 1 In addition, despite curative surgery, around 40-50% of these patients will still relapse within three years of primary surgery. Over the last four decades, 5-fluorouracil (5-FU) has been the cornerstone for CRC treatment in both the palliative and the adjuvant setting. The introduction of new cytotoxic drugs such as capecitabine, irinotecan and oxaliplatin, the integration of biological agents such as cetuximab and bevacizumab and the development of new agents acting on novel targets has clearly increased the number of therapeutic options for patients with advanced and metastatic CRC disease.
Systemic Treatment of Metastatic Disease
The incorporation of new chemotherapeutic and biological agents has raised many important questions and challenges concerning the most effective chemotherapy combination, optimal duration of treatment, optimal use of one or two biological agents in combination chemotherapy and the best sequence.
Combination Chemotherapy
Until the 1990s, the only available drug was 5-FU, with modest activity (response rate [RR] 20-25%, median overall survival [mOS] 13 months) when combined with the biomodulator folinic acid (FA) and delivered as a prolonged infusion 2, 3 (see Figure 1 ). More recently, the oral fluoropyrimidine capecitabine has been shown to be as active as bolus 5-FU/FA. 4 The first real advance came with the addition of irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) to infusion-based 5-FU/FA with response rates in the 40-50% range and mOS times of 17-19 months 5, 6 (see Figure 1) . The cross-over study, conducted by Tournigand et al., provided evidence for increased OS when patients were exposed sequentially to FOLFIRI followed by FOLFOX (mOS 21.5 months) or to FOLFOX followed by FOLFIRI (mOS 20.6 months). 7 In a randomised phase III trial, the triplet combination of irinotecan, oxaliplatin and 5-FU/FA (FOLFOXIRI) was found to be superior to FOLFIRI as first-line treatment with median survival times of 22.6 versus 16.7 months, respectively. 8 In contrast to this study, the phase III trial presented by Souglakis et al. failed to demonstrate any superiority of the FOLFOXIRI arm over the FOLFIRI arm. 9 Phase II studies with infusional 5-FU/FA and bolus mitomycin-C have shown modest activity with response rates of 12-17% in chemo-resistant CRC patients.
Another important challenge has concerned treatment duration: should patients be treated until disease progression, until maximal response or to only a pre-defined dose-limit? In this respect, the OPTIMOX1 trial showed that a planned interruption of oxaliplatin does not compromise the overall efficacy of the treatment. 10 Similarly, a study comparing intermittent FOLFIRI with continuous FOLFIRI administered until disease progression has shown overall survival rates of 16.9 versus 17.6 months, respectively. 11 Ongoing trials such as COIN and CONcePT will further evaluate the approach of treatment interruption.
The Role of Biological Agents

Antiangiogenic Agents
Vascular endothelial growth factor (VEGF) has been identified as a key mediator of angiogenesis, a process essential for growth of tumours and metastasis. Thus, it has become a target for anticancer therapy. 12 The antitumour activity of bevacizumab (Avastin), a humanised IgG1 monoclonal antibody (MAb) directed against VEGF, in combination with first-line chemotherapy has been studied in several phase II-III trials in patients with metastatic CRC. for the chemotherapy arm alone. 16 There was no benefit in response rate for the chemotherapy plus bevacizumab arm. An important and not yet resolved question is whether bevacizumab should be continued following initial response or given as stabilisation to first-line combination bevacizumab-chemotherapy treatment.
Bevacizumab in Chemo-resistant
Colorectal Cancer Patients
Several studies have shown that bevacizumab as monotherapy or in combination with bolus 5-FU/LV is not active in heavily pre-treated patients. 17 A large, randomised, multicentre phase III trial (E3200) showed that bevacizumab plus FOLFOX-4 significantly extended mOS (12.5 versus 10.7 months), progression-free survival (7.2 versus 4.8 months) and overall response rate (21.8 versus 9.2%) compared with the FOLFOX-4 arm alone in CRC patients previously treated with 5-FU and irinotecan. 18 On the basis of this trial, the FDA approved bevacizumab in combination with 5-FU- 
Epidermal Growth Factor Receptor Monoclonal
Antibodies in Chemo-resistant Colorectal Cancer Patients
In contrast to bevacizumab, several phase II trials have demonstrated that cetuximab reverses chemo-resistance when combined with irinotecan in irinotecan-refractory patients. 26, 27 Furthermore, both cetuximab and Colorectal Cancer panitumimab have single-agent activity in heavily pre-treated CRC patients. 26 Similarly to bevacizumab, cetuximab has been shown to increase the activity of an active regimen in the second-line treatment of CRC. The In contrast to the HER1 MAbs, phase II studies have shown that the single-agent HER1-targeted TKIs gefitinib and erlotinib have no substantial activity in chemo-refractory metastatic CRC. 29 While gefitinib has been shown to improve the efficacy of an oxaliplatin-containing regimen as first-and second-/third-line treatment, 30, 31 combining EGFRtargeted TKIs with irinotecan seems to be an inferior option in CRC. 32 Other TKIs with inhibitory activity against both HER1 and HER2, such as lapatinib and CI-1033, are under clinical investigation.
Combination of Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor-targeted Therapies
The 
Best Combination and Optimal Sequence for Epidermal Growth Factor and Vascular Endothelial Growth
Factor-targeted Therapies
The phase III trial by Hurwitz et al. 13 has been the basis for the use of bevacizumab in combination with an active chemotherapeutic regimen in the first-line treatment of patients with metastatic CRC. In view of the BOND studies, the combination of cetuximab plus irinotecan is frequently applied in chemo-refractory CRC. 26, 33 Depending on the performance status of these patients and the potential existence of contraindications for these therapeutic options, several treatment continuum options to extend survival can be recommended (see Figure 2 ).
Beyond Epidermal Growth Factor Receptor and
Vascular Endothelial-targeted Therapies -
Novel Pathways and Agents
Recent advances have been made in the clinical development of therapies designed to inhibit the function of a number of important signalling proteins (see Figure 3) . Other membrane TK receptor targets are the insulin-like growth factor receptor (IGFR) and the platelet-derived growth factor receptor (PDGFR). Several antibody and/or small-molecule inhibitors of both receptors have recently entered clinical trials (see Table 1 ). A Table 1 ). Clinical trials with these agents, as well as with a recombinant version of TRAIL ligand itself (Apo2L/TRAIL), are under way.
Furthermore, several compounds targeting proteins that mediate the extrinsic and mitochondrial death pathway such as B-cell lymphoma 2 (Bcl2) and poly (ADP-Ribose) polymerase (PARP) inhibitors are under clinical investigation (see Table 1 ).
A number of agents were designed to target downstream signalling key targets. Several approaches to inhibit Ras (farnesyltransferase inhibitors, antisense molecules) and Raf failed in the clinic. The multikinase inhibitor sorafinib, several MEK1/2, PI3K, Akt and mammalian target of rapamycin (mTOR) inhibitors are under pre-clinical or clinical investigation (see Table   1 Table 1 ).
Adjuvant Treatment of Colorectal Cancer
Combination Chemotherapy
Based on the data from the INT-0089 trial, bolus 5-FU/LV for six months has been accepted for the adjuvant treatment of stage III colon cancer since the mid-1990s. 34 Three randomised studies compared infusional with bolus administration of 5-FU as adjuvant treatment in stage II-III CRC patients. No difference in disease-free survival (DFS) or OS for any arm was seen; however, continuous infusion of 5-FU had a more favourable toxicity profile. [35] [36] [37] Following this, the X-ACT trial showed a trend towards superior DFS (p=0.0528) and OS (p=0.0706) for capecitabine compared with bolus 5FU/LV in stage III CRC patients. 38 The large-scale QUASAR study of adjuvant chemotherapy versus observation showed a small (3-4%) benefit in five-year survival for stage II CRC patients. 39 Recently, oxaliplatin and irinotecan in combination with a 5-FU-containing regimen have been evaluated in the adjuvant setting. The MOSAIC trial compared FOLFOX4 with infusional 5FU/LV (De Gramont) in stage II-III CRC patients. Only stage III patients benefited from the addition of oxaliplatin to 5FU/LV with a significant difference in four-year DFS of 8.6% (7.2% for N1 disease and 11.2% for N2 disease). In patients with high-risk stage II disease (T4, G3, bowel obstruction, tumour perforation, vascular invasion and number of lymph nodes examined <10), a 5.4% difference in DFS was found between the two groups. 40 In contrast to the oxaliplatin trials, three randomised trials (PETACC-3, ACCORD-02, CALGB 89803) failed to show any benefit in terms of DFS in favour of irinotecan. [41] [42] [43] 
The Role of Biological Agents
Based on the activity of bevacizumab and cetuximab in combination with chemotherapy in the metastatic setting, several ongoing trials are evaluating the effectiveness of bevacizumab or cetuximab as adjuvant treatment (see Table 2 ). 
Conclusion
